A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

Monkeypox disease (MPX) is currently considered a global threat after COVID-19. European Medicines Agency (EMA) approved Tecovirimat in capsule dosage form (200 mg) as the first treatment for MPX in January 2022. This article highlights Tecovirimat’s development and patent literature review and is b...

Descripción completa

Detalles Bibliográficos
Autores principales: Almehmadi, Mazen, Allahyani, Mamdouh, Alsaiari, Ahad Amer, Alshammari, Mohammed Kanan, Alharbi, Abrar Saleh, Hussain, Khansa Hamza, Alsubaihi, Lojain Ibrahim, Kamal, Mehnaz, Alotaibi, Shahad Saleh, Alotaibi, Atheer Nasser, Aldhafeeri, Afeefah Awaid, Imran, Mohd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505384/
https://www.ncbi.nlm.nih.gov/pubmed/36146675
http://dx.doi.org/10.3390/v14091870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505384/
https://www.ncbi.nlm.nih.gov/pubmed/36146675
http://dx.doi.org/10.3390/v14091870

Ejemplares similares